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Intensive chemotherapy or chemotherapy plus irradiation and allogeneic stem cell transplantation can be
curative for patients with hematologic diseases. Reduced-intensity transplants can also achieve cure and
result in less treatment-related mortality but higher relapse rates. Thus, optimizing the conditioning regi-
mens used in allogeneic transplantation remains an important goal. We conducted a phase I/II trial to
determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of a continuous infusion of
busulfan over 90 hours in conjunction with ﬂudarabine followed by allogeneic related or unrelated donor
transplant. Fifty-four patients with advanced hematologic malignancies were enrolled on this study. The MTD
was identiﬁed as a 24-hour area under the curve (AUC) of approximately 7095 mM/min, which represents a
43% increase over the standard total daily AUC dose of 4800 mM/min given by intermittent schedules. DLTs at
doses over 8000 mM/min were identiﬁed by a desquamative skin rash and mucositis. No dose-related increase
in hepatic, pulmonary, or other organ toxicities were seen, whereas efﬁcacy appeared to be improved at
higher dose levels. Continuous-infusion busulfan with intermittent ﬂudarabine provides an alternative
treatment strategy that is generally well tolerated and permits an increase in total busulfan dose with
encouraging efﬁcacy. (NCI study no. NCT00448357.)
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION immunologic dysregulation that results in graft rejection,
The use of high-dose therapy with allogeneic stem cell
transplantation has been shown to be curative in a number of
hematologic diseases. Cure rates of 30% to 70% in different
populations of patients can be identiﬁed, with failure being
attributed either to relapse of the underlying disease or to
treatment-related mortality [1,2]. In some cases the mortal-
ity and morbidity associated with treatment is a result of the
conditioning regimen given before the infusion of donor
stem cells, whereas in other situations it is a result of theedgments on page 2134.
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ty for Blood and Marrow Transplantation.infections, or graft-versus-host disease (GVHD) from infused
donor immune cells. With improvement in therapeutic reg-
imens before transplant and prevention of GVHD, better
antibiotic and transfusion support, and high-resolution HLA
typing, an increasing percentage of treatment failures are the
result of relapse of underlying disease [3-5]. This shift toward
higher disease relapse rates has also resulted from im-
provements in prognostic factors and identiﬁcation of re-
sidual disease in patients with acute and chronic leukemia.
Increasingly, patients who are in better risk categories are
not taken to transplant, because they have a signiﬁcant cure
rate with standard therapy [6]. Relapse has also become an
increasingly important source of treatment failure in the
setting of patients undergoing therapy with either reduced-
intensity or nonablative conditioning regimens, both of
Figure 1. Treatment schema for patients enrolled in our phase I/II study (UNC
LCCC 0510). K indicates Keppra (1 g b.i.d. to start 24 hours before the test
dose to continue through day 2 for seizure prophylaxis); F, ﬂudarabine
(30 mg/m2/day  5 days i.v. infusion over 30 minutes on days 7 through 3);
B, busulfan (dose by continuous i.v. infusion over 90 hours on days 7 to 4.
Patients receive a single dose of busulfan at .8 mg/kg over 2 hours between
days 15 and 10 followed by the targeted 90-hour infusion on days 7 to 4
as described above); T, tacrolimus (target serum levels 3 to 8 ng/mL; suggested
starting dose .03 mg/kg p.o. b.i.d from day 1 to day þ120 and then taper by
day þ180); PBSC, peripheral blood stem cell; A, alemtuzumab (30 patients at a
dose of 30 mg/day  1 or 2 days depending on whether they were a matched
related [1 day] or mismatched related or unrelated [2 days] donorerecipient
pair); M, MTX (5 mg/m2 on daysþ1, þ3, and þ6); ATG, rabbit ATG (.5 mg/kg on
day 3 and 2.5 mg/kg on day 2 [group 2 only]).
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tumor effect to maintain remission status post-transplant
[7-9].
Although data suggest the importance of comorbidities,
age, cytomegalovirus (CMV) status, disease risk, and quality
of donorerecipient match in outcomes [10-12], other data
suggest that conditioning regimen intensity is important in
long-term control of the underlying malignancy [13-16]. In
some diseases, such as acute lymphoblastic leukemia, there
is general agreement that better disease control is provided
by the use of total body radiation but that in most patients
with myeloid disease, any increased beneﬁts in disease
control with total body radiation are offset by a higher like-
lihood of treatment-related morbidity and mortality [17,18].
Nevertheless, because of the high relapse rate in these
advanced malignancies, there continues to be value in
identifying more effective conditioning regimens to control
the underlying disease.
Preclinical data by Teicher et al. [19] demonstrated that
continuous exposure of malignant cells to alkylating agents
in vitro provides a greater cell kill than comparable area
under the curve (AUC) exposure delivered by intermittent
schedules. Clinical data also show that this approach, as
demonstrated by the prolonged infusion of anthracycline in
the EPOCH and VAD regimens, may be associated with better
outcomes and improved tumor control [20-22]. Based on this
work, we postulated that administering busulfan as a pro-
longed infusion might permit a higher total AUC with
reduced toxicity as a result of lower peak concentrations
while still providing greater disease control. In the current
report we describe the results of a phase I/II study report that
assessed the maximum tolerated dose (MTD), toxicities, and
clinical outcomes after the administration of busulfan via a
prolonged infusion schedule in allogeneic transplant pa-
tients with advanced hematologic malignancies.
METHODS
Patients
Patients with advanced, refractory, or high-risk hematologic cancers
who were deemed suitable for myeloablative conditioning and were be-
tween ages 20 and 55 years were eligible for enrollment. All patients pro-
vided appropriate informed consent according to University of North
Carolina Institutional Review Board policies. Patients were stratiﬁed by
disease risk according to American Society for Blood and Marrow Trans-
plantation/Center for International Blood and Marrow Transplant Research
(CIBMTR) criteria [23]. Comorbidity scores were assessed using the Sorror
index [10], and severity of veno-occlusive disease (VOD) was assessed ac-
cording to the Bearman criteria [24]. Patients with other malignancies that
did not qualify for CIBMTR stratiﬁcation required demonstration of high-risk
features or advanced disease beyond complete response for which no other
curative therapy was available. Acute and chronic GVHD scoring were as
outlined by Glucksberg et al. [25] and Shulman et al. [26], respectively.
Busulfan Pharmacokinetic Analysis
A test dose of .8 mg/kg busulfan adjusted for ideal body weight was
administered over 30 minutes followed by plasma levels at baseline, 30
minutes, and 1, 2, 4, and 6 hours after start of the infusion. Based on the AUC
and steady state clearance values obtained with the test dose, targeted AUC
dosing estimated to achieve the desired AUC dosing level per protocol was
then undertaken [27-30]. Within 1 week of the test dose, patients were
admitted for the therapeutic dose and subsequent transplant. Busulfan
plasma concentrations were collected before the start of the 90-hour infu-
sion and then at 30 minutes and 1, 2, 4, 6, 12, 18, 24, 36, 48, 60, 72, 84, 90.5,
92, and 96 hours after start of the infusion. A 90-hour infusionwas chosen to
reﬂect 15/16ths of a full 16-dose schedule, whereas the test dose repre-
sented 1/16th of the full 16-dose schedule. All whole blood samples were
centrifuged at 1000 g for 10 minutes at 4C, and aliquots of plasma were
collected and stored at 80C until analysis. Busulfan concentrations were
quantiﬁed at Emory University Hospital using high-pressure gas chroma-
tography [30]. The lower limit of quantitation was .1 mmol/L, and the assay
was linear between .1 and 20.0 mmol/L. AUC calculations were assessed forthe test dose and on the ﬁrst 6 hours of therapeutic infusion, and dosages
were adjusted for hours 42 through 90 after return of the initial AUC values
if they were more than 10% above or below the desired range.
Individual busulfan plasma concentrations were used to estimate the
following pharmacokinetic (PK) parameters using a noncompartmental
model on WinNonlin 4.0 (Pharsight Corp., Mountain View, CA): maximum
plasma concentration, area under the concentration-time curve through the
last measurable time point (AUC), terminal half-life, and whole blood
clearance. The AUCwas calculated using the log-linear trapezoidmethod. All
AUC and clearance data were natural log-transformed and reported using
descriptive statistics.Statistical Considerations
In the phase I portion of the study, patients were dosed in cohorts ac-
cording to the 5 target AUC levels. Additional patients were enrolled at dose
level 1 (standard dose) during the phase I and II portions of the study if their
insurance coverage did not allow enrollment onto a phase I study. The MTD
was deﬁned as the dose with the dose-limiting toxicity (DLT) rate of .25.
A dose assignment strategy that allowed for delayed toxicity outcome was
used [31]. Initial escalation was in cohorts of 3 patients until at least 1 pa-
tient developed a DLT. After the initial dose escalation, patients were
assigned to the current dose cohort if estimated DLT rate at the current dose
was between .15 and .35. The dose was increased or decreased if the esti-
mated DLT rate at the current dose was below .15 or higher than .35.
The sample size for phase I was set at 35 patients. An additional 25
patients were enrolled to the estimated MTD. During the phase II portion of
the trial, the rate of nonrelapse mortality at day 100 was monitored using
the Pocock boundary to stop the trial if the rate was too high [32]. Similarly,
the rate of irreversible grade 3 toxicity or grade 4 toxicity lasting more than
2 weeks was monitored. The acceptable rate for each was set to .2.Treatment
In addition to busulfan, all patients also received daily ﬂudarabine at a
dose of 30 mg/m2/day  5 according to the schedule outlined in Figure 1.
All patients received GVHD prophylaxis with tacrolimus starting on
day 1 and targeted to maintain serum levels of 3 to 8 mg/dL. Patients
received either alemtuzumab at a dose of 30 mg/day  1 or 2 days
depending on whether they were a matched related (1 day) or mis-
matched related or unrelated (2 days) donorerecipient pair. After the ﬁrst
30 patients were enrolled, because of concerns over a high rate of viral
infections, matched related patients received methotrexate (MTX) and
tacrolimus alone and mismatched related or unrelated patients received
tacrolimus, MTX þ antithymocyte globulin (ATG). MTX was given at a dose
of 5 mg/m2 on days þ1, þ3, and þ6 [33].
Table 1
Patient Demographics according to Measured Busulfan AUC Dose
Total No. of Patients AUC
Low (5078 mM/min) Intermediate (6372 mM/min) High (7605 mM/min)
No. of patients 54 18 18 18
F/M 20/34 9/9 3/15 8/10
Median age, yr 40 37 40 45
Host CMV status 18 neg, 36 pos 8 neg, 10 pos 4 neg, 14 pos 6 neg, 12 pos
Donorerecipient sex 6 MeF
12 FeM
22 MeM
14 FeF
2 MeF
2 FeM
7 MeM
7 FeF
1 MeF
6 FeM
9 MeM
2 FeF
3 MeF
4 FeM
6 MeM
5 FeF
Disease histology
AML/MDS/CML 26/8/1 5/5/0 9/2/0 12/1/1
ALL 7 6 1 0
NHL/HD 5/2 0/0 3/2 2/0
MF/CLL/CMML 1/1/1 0/1/0 0/0/1 1/0/0
PCL 2 1 0 1
Type of transplant
MUD 34 11 10 13
MRD 20 7 8 5
Median CMI 2 1 2 2
Disease risk
Low 16 8 4 4
Intermediate 20 5 7 8
High 18 5 7 6
AML indicates acute myelogenous leukemia; MDS, myelodysplasia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia; NHL/HD, non-
Hodgkin/Hodgkin lymphoma; MF, myeloﬁbrosis; CLL, chronic lymphoblastic leukemia; CMML, chronic myelomonocytic leukemia; PCL, plasma cell leuke-
mia; MUD, matched related donor; MRD, matched unrelated donor; CMI, comorbidity index.
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Demographics
Fifty-four patients with myeloid malignancy (36 pa-
tients), acute lymphoblastic leukemia (7 patients), non-
Hodgkin or Hodgkin lymphoma (7 patients), and a variety
of myeloproliferative diseases or prolymphocytic leukemia
(4 patients) were enrolled on this study (Table 1). Patients
received alemtuzumab in addition to tacrolimus (30 pa-
tients), tacrolimus plus ATG and MTX (18 patients), or MTX
and tacrolimus alone (6 patients). Thirty-four patients
received transplants from matched unrelated donors and 20
received a matched related donor transplant. All recipients
received peripheral blood stem cells. Median age of the
entire patient population was 40, with 20 women and 34
men. Additional details of host and donor CMV status,
donorerecipient sex, diagnosis, comorbidity index, and dis-
ease risk are listed in Table 1. Data are presented for each of 3
measured busulfan AUC doses delivered and divided into
low, intermediate, and high AUC dose cohorts.Table 2
AUC and DLTs by Planned AUC Dose Levels
Dose Level n Goal (Actual Range) 90-Hour Mean
AUC (mM/min)
Precision DLTs
1 14 4800 (3933-6302) 4973 11.7% 1
2 7 5760 (5231-6081) 5620 4.9% 1
3 24 6912 (5705-8268) 7095 10.2% 1
4 7 7603 (6056-8255) 7000 11.1% 2
5 2 8363 (7243-8863) 8680 15.9% 2PK Measurements and MTD Determinations
All 54 patients underwent test dose administration and
PK measurements that were performed 4 to 7 days before
initiating therapeutic dosing of busulfan. A total of 5 AUC
levels ranging from a low dose of 4800 mM/min to a high of
8363 mM/min were delivered. Dose level 3, at a targeted AUC
of 6912 mM/min, was identiﬁed as the MTD for this regimen
(Table 2). The actual average dose delivered by continuous
infusion at dose level 3 was 7095 mM/min. Dose targeting
precisionwas estimated by root mean squared error and was
10.2% for that dose. Within-day and between-day variability
measured by coefﬁcient of variation were below 10% for all
busulfan concentrations. Patients enrolled on each dose level
were listed in Table 2 according to the targeted AUC
administered. Fourteen patients were enrolled at dose level
1, including 11 who were enrolled after escalation to subse-
quent dose levels had occurred to capture PK and phase IIdata on patients whose insurance companies precluded their
participation in a phase I or dose escalation study.
Toxicity and MTD
The initial dose escalations were undertaken in 5 separate
cohorts with AUC targeted ranges varying from a low of
4800 mM/min to a high of 8363 mM/min delivered per
24 hours. Because the purpose of this trial was to deﬁne an
AUC-directed dose of chemotherapy by continuous infusion,
toxicities were determined and reported for each of these
cohorts during the initial dose escalation portion of the trial
(Table 2). Two patients on the original ﬁfth dose level
experienced grade 4 DLT of mucositis and a desquamative,
intertriginous skin rash that developed between days
0 and þ10. As a result, additional subjects were enrolled at
dose level 4. When 2 additional DLT cases of grade 4 muco-
sitis were identiﬁed at the original fourth dose level, an AUC
goal of 7603 mM/min, it was determined that the third dose
level with a target AUC of 6912 mM/min and an actual AUC of
7095 mM/minwas theMTD. Of the 24 patients treated at dose
level 3, a grade 5 case of VODwas seen. No other grade 4 or 5
regimen-related toxicities were observed at this dose level.
Because AUC levels varied between the groups and the
goal was to identify an actual achieved AUC-based dose,
additional outcome analyses were undertaken by dividing
patients into thirds according to the actual AUCs delivered
rather than the original planned AUCs (Table 3). Although we
Table 3
Toxicities and Outcomes by Measured AUCs
AUC Tertile Total (n ¼ 54) Low (n ¼ 18) Intermediate (n ¼ 18) High (n ¼ 18)
AUC measured, mM/min 5078 (3933-5615) 6372 (5639-6965) 7605 (7054-8863)
Grade 4 mucositis 4 1 1 2
Grade 5 VOD/liver failure 3 1 (sepsis/liver failure) 1 (VOD) 1 (VOD)
Treatment-related mortality (GVH, infection, pneumonitis, VOD) 18 (33%) 6 (33%) 6 (33%) 6 (33%)
GVHD prophylaxis: tacrolimusþ
Alemtuzumab 30 15 10 5
ATG þ MTX 18 3 6 9
MTX 6 0 2 4
Acute GVHD grade  II 28 (52%) 7 (39%) 10 (56%) 11 (61%)
Acute GVHD grades III and IV 9 (17%) 2 (11%) 4 (22%) 3 (17%)
Chronic GVH; intermediate/severe 12 (22%) 4 (22%) 6 (33%) 2 (11%)
OS rate at 3 years .42 .28 .39 .55
RFS rate at 3 years .36 .22 .39 .43
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linear effect of AUC on the hazard function, the assumption
that AUC affected the hazard function in a linear manner was
incorrect, and therefore we presented results for the AUC
levels divided into thirds. This post-hoc analysis provided
larger numbers per group and allowed for more robust
analysis and comparisons of both safety and efﬁcacy ac-
cording to the actual dose delivered rather than the planned
dose level. With this analysis, the lowest third comprised 18
patients who received a median AUC dose of 5078 mM/min of
busulfan, the middle third contained 18 patients who
received a median dose of 6372 mM/min of busulfan, and the
highest third comprised 18 patients with a median AUC of
7605 mM/min. Grades 4 and 5 life-threatening or fatal tox-
icities were seen in 2 patients in the lowest third who had
VOD and severe mucositis. In the intermediate dose level, 1
patient had grade 4 mucositis and 1 had severe VOD,
whereas in the highest third there was 1 fatal case of VOD
and 2 cases of grade 4 mucositis. The individuals in the
highest third with grade 4 mucositis both had AUCs in excess
of 8600 mM/min. Engraftment was as expected in all cohorts,
with a median time to neutral count greater than 1000 of
13 days and platelet count greater than 20,000 without
transfusion of 15 days.
Graft-versus-Host Disease
Thirty of 54 patients were treatedwith alemtuzumab, and
29 of them lived to day 100 and were fully assessable for
GVHD. Of these 29 patients, 11 (38%) developed grade II acute
GVHD and 2 (7%) grade III or IV acute GVHD, whereas 6 pa-
tients (21%) developed extensive chronic GVHD and 3 (10%)
had limited chronic GVHD (Table 3). Six patients (21%) had
grade I GVHD and 7 (24%) had no acute or chronic GVHD.
Eighteen patients received ATG, and 2 developed grade I
acute GVHD, 5 (28%) developed grade II acute GVHD, 2 (11%)
developed grade III acute GVHD, and 3 (17%) developed grade
IV acute GVHD. Two patients developed chronic extensive
GVHD. Four patients had no acute or chronic GVHD. Six
additional patients received no ATG or alemtuzumab after
transplantation with a matched related donor. Of these pa-
tients, 2 (33%) had grade I, 2 (33%) grade II, 1 (17%) grade III,
and 1 (17%) grade IV acute GVHD. One of these patients (17%)
developed extensive chronic GVHD, and none was without
any GVHD.
Chimerism
Of the 54 enrolled and assessable patients, 49 had whole
blood chimerism and 46 had T cell chimerism measured atday 30 (Table 3). Forty-seven of 49 had 95% donor chime-
rism in the whole blood compartment, and 30 of 45 had
95% donor chimerism in the T cell compartment. Of the
remaining samples analyzed for whole blood chimerism, 2
were <95% donor (21% and 54%) and 15 of 45 had <95%
donor T cells (range, 27% to 94%). At day 100, 40 of 45
assessable patients had95% donor whole blood chimerism,
and 25 of 42 had >95% donor in the T cell compartment.
Seventeen of 42 patients were <95% donor T cell chimeras
(range, 1% to 91%). There were no differences in chimerism
results as a function of either the immunosuppression used
or busulfan dose received.
Outcomes
The purpose of this studywas to identify the DLTandMTD
along with identifying the potential value of higher doses of
busulfan when administered as a prolonged i.v. infusion.
Sixteen subjects had low, 20 had intermediate, and 18 had
high-risk disease by CIBMTR criteria (Table 1). Rates of un-
adjusted overall survival (OS) and relapse-free survival (RFS)
for all 54 subjects were .42 and .36, respectively. When
analyzed according to the AUC low (group 1, 18 patients),
middle (group 2, 18 patients), or high (group 3, 18 patients)
dose (Table 4), rates of OS were .28, .39, and .55 and of RFS
.22, .39, and .43, respectively (not signiﬁcant for all analyses).
For the entire group, univariate analysis identiﬁed age,
recipient CMV status, and disease risk as signiﬁcant factors
for OS and RFS (Table 3). Comorbidity scores, diagnosis, GVH
occurrence, donorerecipient sex, and donor type (matched
unrelated or matched related) were not signiﬁcant. Also, the
nonrelapse mortality and OS rates were not different be-
tween the 3 AUC groups in univariate analysis. The use of
alemtuzumab versus ATG did not affect OS or relapse rates,
with hazard ratios of 1.48 and 1.55 and P ¼ .27 and .21,
respectively. Adjusted analysis by AUC group identiﬁed high
versus low AUC dose (P ¼ .049) and disease risk (P ¼ .01) as
signiﬁcant for both OS and RFS (Table 4, Figure 2). Outcomes
were similar between AUC groups 2 (intermediate) and 3
(high). Differences in OS and RFS were limited to the good-
and intermediate-risk patients because outcomes for high-
risk patients were poor for all AUC groups (1/18 OS and
0/18 RFS). Similar results were obtained when these analyses
were performed according to targeted rather than measured
AUC (data not shown).
DISCUSSION
The value of allogeneic stem cell transplantation has
traditionally been derived from a combination of the
Table 4
Cox Regression Analysis for Effect of Univariable and Multivariable Risk Factors on OS and RFS
Model Covariate OS RFS
HR 95% CI P HR 95% CI P
Univariate analysis AUC (2 vs. 1) .94 (.42-2.08) .88 .90 (.41-1.95) .78
AUC (3 vs. 1) .59 (.25-1.36) .21 .58 (.26-1.31) .19
AUC (3 vs. 2) .62 (.26-1.51) .30 .64 (.28-1.50) .31
GVHD prophy .64 (.32-1.30) .21 .61 (.31-1.21) .16
Donor 1.48 (.75-2.93) .26 1.73 (.89-3.37) .11
Age 1.04 (1.00-1.07) .04 1.04 (1.01-1.08) .01
CMV 3.22 (1.40-7.43) .01 2.98 (1.34-6.59) .01
GC .97 (.42-2.23) .94 .89 (.40-1.99) .78
GVHD 1.11 (.51-2.41) .78 1.06 (.51-2.22) .87
CMI 1.16 (.73-1.84) .54 1.12 (.72-1.75) .62
Diagnosis* .81 (.41-1.6) .54 .81 (.42-1.58) .54
Disease risky 2.42 (1.51-3.88) <.01 2.93 (1.78-4.83) <.01
Adjusted analysis AUC (2 vs. 1) .79 (.35-1.76) .56 .57 (.25-1.28) .17
AUC (3 vs. 1) .42 (.18-1.00) .049 .34 (.14-.79) .01
AUC (3 vs. 2) .54 (.22-1.33) .18 .59 (.25-1.40) .23
Age 1.01 (.97-1.05) .65 1.02 (.99-1.06) .18
CMV 2.05 (.85-4.94) .11 1.97 (.86-4.54) .11
Disease risk 2.16 (1.24-3.75) .01 2.75 (1.56-4.88) <.01
HR indicates hazard ratio; CI, conﬁdence interval; GC, donorerecipient gender pairing.
P values < .05 appear in bold.
* Diagnosis: AML þ MDS vs. others.
y Disease risk according to American Society for Blood and Marrow Transplantation/CIBMTR criteria [23].
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derlying disease, permit durable donor engraftment, and
confer an antitumor effect (graft-versus-tumor) from the
donor cell infusion. In recent years the use of reduced-
intensity regimens have permitted the expansion of alloge-
neic transplants into populations of older and less robust
patients and provide a cure for a signiﬁcant population that
had not previously been eligible for such therapy. The rates of
cancer relapse after reduced-intensity conditioning he-
matopoietic cell transplantation remains unacceptably high,
however [1,3,4], and appear to be higher compared with
myeloablative regimens for certain diseases [13,14,16]. Evi-
dence suggests that more intensive regimens are associated
with improved disease control for those patients who are in
better health and able to tolerate these therapies, particularly
for advanced diseases such as relapsed and refractory lym-
phomas or high-risk acute myeloid and lymphoid leukemias.
Although retrospective data have suggested that the OS rates
are comparable in patients over age 50 treated with fully
ablative or reduced-intensity regimens, a recent trial by the
Bone Marrow Transplant Clinical Trials Network (CTN 0901)
was stopped early because of an apparent increase in early
relapse rates in the population getting less-intensive thera-
pies (unpublished data). Details of this study are not yet
available, but it implies that intensive regimens continue to
be valuable, particularly because relapse remains the major
cause of treatment failure in this patient population.
In the current study, a novel approach for administration of
a highly effective chemotherapyagent, i.v. busulfan, alongwith
the immunosuppressant ﬂudarabine was used as a means to
allowpotential dose escalation of this drug forhealthy patients
under age 55 compared with four times a day or once a day
administration schedules. Investigators at MD Anderson
identiﬁed an AUC MTD of 6000 by once-daily infusion in
conjunction with ﬂudarabine as an appropriate dose for
youngerandhealthier individuals. In our studywewere able to
administer i.v. busulfan as a continuous infusion over 90 hours
at a phase II MTD of approximately 7000 mM/min AUC per
24 hours for a total AUC exposure of 26,250 mM/min plus the
test dose of approximately 1200 mM/min. This resulted in atotal busulfan dose of approximately 27,500 mM/min and
represents a 15% increase over the AUC identiﬁed by the MD
Anderson investigators and a 43% increaseover a standardAUC
of 4800 mM/min/day [17,34,35].
In addition to this higher total dose of drug, the prolonged
administration schema may result in improved cell kill, as
reported by Teicher et al. [19] with preclinical testing of
models using a variety of cell lines. Although the results
obtained in this trial do not permit conclusions regarding the
antitumor efﬁcacy of this approach, they indicate that a
higher and potentially more effective dose can be adminis-
tered safely with the continuous infusion schema described
in this study. It is also appreciated that the results at the
lowest AUCmay be poorer than expected and that prolonged
infusion may be less effective at standard doses than inter-
mittent schedules, but with small numbers and disease
heterogeneity it is not possible to provide a deﬁnitive anal-
ysis of these outcomes.
It is important to point out that there did not appear to be
a signiﬁcant increase in toxicity associated with these higher
doses of drugs until the delivery of AUC doses above
8000 mM/min/day, at which timewe identiﬁedmucositis and
skin rash as the DLTs. An intertriginous rash associated with
grade 4 mucositis was seen in both patients treated at AUCs
> 8000 mM/min over 24 hours and suggests that GVHD
prophylaxis regimens that avoid MTX or other mucositis
enhancing agents may be useful in limiting this signiﬁcant
source of morbidity andmortality. If additional patients were
enrolled at these levels, it is likely that further organ toxic-
ities such as hepatic or pulmonary damage would have been
seen; it was notable, however, that neither signiﬁcant VOD of
the liver nor interstitial pneumonitis was seen with an
increased frequency at the higher dose levels. There was 1
case of severe VOD at the lowest AUC cohort and 1 case at the
highest dose level. A third case that was observed at the in-
termediate dose level was believed to represent hepatic
failure in conjunction with sepsis and multiorgan failure.
Although early pulmonary complications without an iden-
tiﬁable infectious agent were contributors to the death of 2
subjects, whether this was from busulfan or other
Figure 2. Kaplan-Meier curves by (top) OS and (bottom) RFS.
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surviving patients have developed pulmonary complica-
tions in the presence of GVHD, but thesewere not believed to
be due to busulfan. Other attendant morbidities such as
GVHD and infectious complications were observed at a rate
that is consistent with what would be expected using abla-
tive regimens. There was no excess mortality associated with
alemtuzumab, but its use was discontinued after the ﬁrst 30
patients because of an accompanying increase in viral in-
fections and related complications.
In summary, the use of prolonged infusion busulfan ap-
pears to allow for a higher MTD compared with intermittent
busulfan infusion schedules. Further trials to reﬁne and
reduce the complications seen, such as mucositis and skin
rash, at the highest dose levels are being considered along
with efforts to optimize the efﬁcacy of this approach. Other
than the challenge of administering a continuous infusion of
a drug that requires preparation 2 to 3 times a day, nosigniﬁcant complications were seen with this approach that
were not also attributable to the higher doses. The use of a
test dose before initiation of treatment appears to be
important to identify the appropriate range for adminis-
tering this drug because our study determined that the
general accuracy of the AUC based on the busulfan clearance
was found to be in excess of 90%. This approach holds
promise as a treatment regimen that is tolerable and may
diminish relapse rates in this population of patients with
high-risk hematologic cancers.ACKNOWLEDGMENTS
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